Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

NCT05147896 is registered in ClinicalTrials.gov with University Medical Centre Ljubljana as lead sponsor.

NCT NCT05147896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05147896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients
Lead sponsor
University Medical Centre Ljubljana
Phase
Not applicable
Overall status
Unknown status
Start date
May 1, 2022
Completion date
December 1, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, diabetes mellitus, type 2